Aventis Tripacel
Executive Summary
Diphtheria, tetanus and acellular pertussis vaccine will be reviewed Nov. 3 by FDA's Vaccines & Related Biological Products Advisory Committee. "The Pink Sheet" (Oct. 9, In Brief) misidentified the product trade name. The acellular pertussis component of Tripacel differs from the component in Aventis' marketed DTaP vaccine Tripedia. Aventis said it hopes Tripacel, under review at FDA, will provide the foundation for its future pediatric combination vaccines